Somewhat Positive Media Coverage Somewhat Unlikely to Impact Crispr Therapeutics (CRSP) Stock Price

News headlines about Crispr Therapeutics (NASDAQ:CRSP) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Crispr Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.2379440024473 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern’s rankings:

Crispr Therapeutics stock opened at $52.16 on Thursday. The company has a market capitalization of $2,420.20, a price-to-earnings ratio of -30.33 and a beta of 3.63. Crispr Therapeutics has a fifty-two week low of $13.50 and a fifty-two week high of $61.24.

A number of research firms have issued reports on CRSP. TheStreet upgraded Crispr Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, March 16th. Zacks Investment Research raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. Piper Jaffray Companies reissued a “buy” rating and set a $22.75 price target (down from $39.00) on shares of Crispr Therapeutics in a report on Wednesday, January 10th. SunTrust Banks reissued a “buy” rating and set a $65.00 price target on shares of Crispr Therapeutics in a report on Friday, March 9th. Finally, Barclays raised their price target on Crispr Therapeutics from $29.00 to $59.00 and gave the company an “overweight” rating in a report on Wednesday, March 7th. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Crispr Therapeutics has a consensus rating of “Buy” and a consensus target price of $53.53.

In other news, insider Tyler Dylan-Hyde sold 15,000 shares of the firm’s stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $20.55, for a total transaction of $308,250.00. Following the transaction, the insider now directly owns 115,204 shares of the company’s stock, valued at $2,367,442.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Aktiengesellschaft Bayer bought 527,472 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were purchased at an average cost of $22.75 per share, for a total transaction of $11,999,988.00. The disclosure for this purchase can be found here. Insiders have sold 283,850 shares of company stock worth $7,261,865 over the last three months. Corporate insiders own 39.98% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply